Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics will still submit tovecimig for approval despite the OS miss.
Therapy Area
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
Africa-Europe partnership delivers first clinical trial for malaria in early pregnancy
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
ESCMID Global 2026: Olorofim targets invasive Aspergillus in hematology patients
AAN 2026: BlueRock reports positive safety data for bemdaneprocel in Parkinson’s
AAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competition
AAN 2026: new Vyvgart data show disease control in seronegative gMG
